Madrigal Pharmaceuticals Stock Price on March 21, 2024
| MDGL Stock | USD 313.11 0.93 0.30% |
Below is the normalized historical share price chart for Madrigal Pharmaceuticals extending back to February 06, 2007. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Madrigal Pharmaceuticals stands at 313.11, as last reported on the 29th of December, with the highest price reaching 317.67 and the lowest price hitting 308.12 during the day.
If you're considering investing in Madrigal Stock, it is important to understand the factors that can impact its price. Madrigal Pharmaceuticals appears to be very steady, given 3 months investment horizon. Madrigal Pharmaceuticals has Sharpe Ratio of 0.15, which conveys that the firm had a 0.15% return per unit of risk over the last 3 months. By analyzing Madrigal Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.7% is justified by implied risk. Please exercise Madrigal Pharmaceuticals' Risk Adjusted Performance of 0.1244, mean deviation of 2.58, and Downside Deviation of 2.36 to check out if our risk estimates are consistent with your expectations.
At this time, Madrigal Pharmaceuticals' Common Stock is quite stable compared to the past year. Stock Based Compensation is expected to rise to about 52.2 M this year, although the value of Sale Purchase Of Stock will most likely fall to about 256.7 K. . At this time, Madrigal Pharmaceuticals' Price To Sales Ratio is quite stable compared to the past year. Price Book Value Ratio is expected to rise to 11.20 this year, although the value of Price Earnings To Growth Ratio is projected to rise to (0.76). Madrigal Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 6th of February 2007 | 200 Day MA 257.7841 | 50 Day MA 294.7034 | Beta (0.47) |
Madrigal |
Sharpe Ratio = 0.1546
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MDGL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.55 actual daily | 40 60% of assets are more volatile |
Expected Return
| 0.7 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average Madrigal Pharmaceuticals is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Madrigal Pharmaceuticals by adding it to a well-diversified portfolio.
Price Book 8.7873 | Enterprise Value Ebitda (8.32) | Price Sales 88.9049 | Shares Float 10.7 M | Wall Street Target Price 373 |
Madrigal Pharmaceuticals Main Headline on 21st of March 2024
Acquisition by Baker Bros. Advisors Lp of 86741 shares of Ma... by Baker Bros. Advisors Lp
Filed transaction by Madrigal Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Madrigal Pharmaceuticals Valuation on March 21, 2024
It is possible to determine the worth of Madrigal Pharmaceuticals on a given historical date. On March 21, 2024 Madrigal was worth 261.64 at the beginning of the trading date compared to the closed value of 255.27. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Madrigal Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Madrigal Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Madrigal Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Madrigal Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 267.50 | 267.50 | 251.01 | 258.99 | 675,304 | |
03/21/2024 | 261.64 | 265.79 | 251.79 | 255.27 | 382,339 |
| 258.49 | 259.95 | 242.38 | 248.20 | 529,991 |
| Backtest Madrigal Pharmaceuticals | | | Madrigal Pharmaceuticals History | | | Madrigal Pharmaceuticals Valuation | Previous | Next |
Madrigal Pharmaceuticals Trading Date Momentum on March 21, 2024
| On March 22 2024 Madrigal Pharmaceuticals was traded for 248.20 at the closing time. The top price for the day was 259.95 and the lowest listed price was 242.38 . The trading volume for the day was 530 K. The trading history from March 22, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 2.77% . The trading delta at closing time against the current closing price is 4.70% . |
Madrigal Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Madrigal Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Madrigal Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Madrigal financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Madrigal Pharmaceuticals Stock history
Madrigal Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Madrigal is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Madrigal Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Madrigal Pharmaceuticals stock prices may prove useful in developing a viable investing in Madrigal Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 18.7 M | 19.6 M | |
| Net Loss | -265.8 M | -252.5 M |
Madrigal Pharmaceuticals Quarterly Net Working Capital |
|
Madrigal Pharmaceuticals Stock Technical Analysis
Madrigal Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Madrigal Pharmaceuticals Period Price Range
Low | December 29, 2024
| High |
0.00 | 0.00 |
Madrigal Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Madrigal Pharmaceuticals December 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Madrigal Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Madrigal Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Madrigal Pharmaceuticals stock market strength indicators, traders can identify Madrigal Pharmaceuticals entry and exit signals to maximize returns
Madrigal Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Madrigal Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Madrigal Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Madrigal to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1244 | |||
| Jensen Alpha | 0.6213 | |||
| Total Risk Alpha | 0.5184 | |||
| Sortino Ratio | 0.2632 | |||
| Treynor Ratio | 0.6514 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.